Advertisement
Advertisement

NUVB

NUVB logo

Nuvation Bio Inc.

4.78
USD
Sponsored
-0.06
-1.24%
May 13, 15:59 UTC -4
Closed
exchange

Pre-Market

4.84

+0.06
+1.36%

NUVB Earnings Reports

Positive Surprise Ratio

NUVB beat 14 of 21 last estimates.

67%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$27.88M
/
-$0.18
Implied change from Q1 26 (Revenue/ EPS)
-66.50%
/
-1900.00%
Implied change from Q2 25 (Revenue/ EPS)
+476.88%
/
+5.88%

Nuvation Bio Inc. earnings per share and revenue

On May 04, 2026, NUVB reported earnings of 0.01 USD per share (EPS) for Q1 26, beating the estimate of 0.00 USD, resulting in a 8.70% surprise. Revenue reached 83.23 million, compared to an expected 63.50 million, with a 31.06% difference. The market reacted with a +9.52% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 27.88 million USD, implying an decrease of -1900.00% EPS, and decrease of -66.50% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
logo
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
logo
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
logo
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
logo
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
logo
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-
Actual
-$0.05
Surprise
-
logo
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
logo
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
logo
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
For Q1 2026, Nuvation Bio Inc. reported EPS of $0.01, beating estimates by 8.7%, and revenue of $83.23M, 31.06% above expectations.
The stock price moved up 9.52%, changed from $4.41 before the earnings release to $4.83 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 8 analysts, Nuvation Bio Inc. is expected to report EPS of -$0.18 and revenue of $27.88M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement